Logo image of TLRY

TILRAY BRANDS INC (TLRY) Stock Fundamental Analysis

NASDAQ:TLRY - Nasdaq - US88688T1007 - Common Stock - Currency: USD

0.6856  -0.02 (-2.45%)

Fundamental Rating

2

Taking everything into account, TLRY scores 2 out of 10 in our fundamental rating. TLRY was compared to 194 industry peers in the Pharmaceuticals industry. TLRY has a bad profitability rating. Also its financial health evaluation is rather negative. TLRY is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year TLRY has reported negative net income.
TLRY had a negative operating cash flow in the past year.
In the past 5 years TLRY always reported negative net income.
TLRY had negative operating cash flow in 4 of the past 5 years.
TLRY Yearly Net Income VS EBIT VS OCF VS FCFTLRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B

1.2 Ratios

The Return On Assets of TLRY (-27.79%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -34.64%, TLRY is in the better half of the industry, outperforming 60.31% of the companies in the same industry.
Industry RankSector Rank
ROA -27.79%
ROE -34.64%
ROIC N/A
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
TLRY Yearly ROA, ROE, ROICTLRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

TLRY has a Gross Margin (30.88%) which is comparable to the rest of the industry.
TLRY's Gross Margin has declined in the last couple of years.
TLRY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
TLRY Yearly Profit, Operating, Gross MarginsTLRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

3

2. Health

2.1 Basic Checks

TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TLRY has more shares outstanding
TLRY has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TLRY has an improved debt to assets ratio.
TLRY Yearly Shares OutstandingTLRY Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
TLRY Yearly Total Debt VS Total AssetsTLRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

TLRY has an Altman-Z score of -0.54. This is a bad value and indicates that TLRY is not financially healthy and even has some risk of bankruptcy.
TLRY has a Altman-Z score (-0.54) which is comparable to the rest of the industry.
TLRY has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
TLRY has a Debt to Equity ratio of 0.11. This is comparable to the rest of the industry: TLRY outperforms 48.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -0.54
ROIC/WACCN/A
WACC9.46%
TLRY Yearly LT Debt VS Equity VS FCFTLRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

2.3 Liquidity

A Current Ratio of 2.62 indicates that TLRY has no problem at all paying its short term obligations.
TLRY has a Current ratio of 2.62. This is comparable to the rest of the industry: TLRY outperforms 44.85% of its industry peers.
A Quick Ratio of 1.61 indicates that TLRY should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.61, TLRY is not doing good in the industry: 61.86% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.62
Quick Ratio 1.61
TLRY Yearly Current Assets VS Current LiabilitesTLRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

5

3. Growth

3.1 Past

TLRY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.41%, which is quite impressive.
The Revenue has grown by 11.23% in the past year. This is quite good.
TLRY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 78.86% yearly.
EPS 1Y (TTM)25.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%-1.36%

3.2 Future

Based on estimates for the next years, TLRY will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.67% on average per year.
TLRY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.68% yearly.
EPS Next Y-288.38%
EPS Next 2Y13.17%
EPS Next 3Y18.09%
EPS Next 5Y18.67%
Revenue Next Year8.42%
Revenue Next 2Y7.1%
Revenue Next 3Y6.28%
Revenue Next 5Y5.68%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TLRY Yearly Revenue VS EstimatesTLRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TLRY Yearly EPS VS EstimatesTLRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

1

4. Valuation

4.1 Price/Earnings Ratio

TLRY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TLRY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLRY Price Earnings VS Forward Price EarningsTLRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TLRY indicates a somewhat cheap valuation: TLRY is cheaper than 79.38% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 30.29
TLRY Per share dataTLRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

A more expensive valuation may be justified as TLRY's earnings are expected to grow with 18.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.17%
EPS Next 3Y18.09%

0

5. Dividend

5.1 Amount

TLRY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

TILRAY BRANDS INC

NASDAQ:TLRY (7/25/2025, 3:11:08 PM)

0.6856

-0.02 (-2.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-08 2025-04-08/bmo
Earnings (Next)07-28 2025-07-28/amc
Inst Owners10.08%
Inst Owner Change-0.56%
Ins Owners0.31%
Ins Owner Change1.17%
Market Cap703.10M
Analysts72.94
Price Target1.33 (93.99%)
Short Float %20.28%
Short Ratio6.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-140.2%
Min EPS beat(2)-145.1%
Max EPS beat(2)-135.29%
EPS beat(4)0
Avg EPS beat(4)-91.89%
Min EPS beat(4)-145.1%
Max EPS beat(4)-8.93%
EPS beat(8)1
Avg EPS beat(8)-85.68%
EPS beat(12)1
Avg EPS beat(12)-398.32%
EPS beat(16)4
Avg EPS beat(16)-256.75%
Revenue beat(2)0
Avg Revenue beat(2)-8.97%
Min Revenue beat(2)-13.28%
Max Revenue beat(2)-4.66%
Revenue beat(4)0
Avg Revenue beat(4)-7.31%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)-0.75%
Revenue beat(8)1
Avg Revenue beat(8)-2.67%
Revenue beat(12)1
Avg Revenue beat(12)-3.36%
Revenue beat(16)1
Avg Revenue beat(16)-7.96%
PT rev (1m)2.16%
PT rev (3m)-31.51%
EPS NQ rev (1m)6.68%
EPS NQ rev (3m)6.68%
EPS NY rev (1m)-20.44%
EPS NY rev (3m)-26.52%
Revenue NQ rev (1m)-0.33%
Revenue NQ rev (3m)-0.33%
Revenue NY rev (1m)-0.12%
Revenue NY rev (3m)-1.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.85
P/FCF N/A
P/OCF N/A
P/B 0.26
P/tB 1.21
EV/EBITDA 30.29
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0.81
BVpS2.66
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.79%
ROE -34.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.88%
FCFM N/A
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA 12.7
Cap/Depr 27.68%
Cap/Sales 4.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.62
Quick Ratio 1.61
Altman-Z -0.54
F-Score4
WACC9.46%
ROIC/WACCN/A
Cap/Depr(3y)20.35%
Cap/Depr(5y)159.29%
Cap/Sales(3y)4.15%
Cap/Sales(5y)16.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y-288.38%
EPS Next 2Y13.17%
EPS Next 3Y18.09%
EPS Next 5Y18.67%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%-1.36%
Revenue Next Year8.42%
Revenue Next 2Y7.1%
Revenue Next 3Y6.28%
Revenue Next 5Y5.68%
EBIT growth 1Y-239.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year133.02%
EBIT Next 3Y37.28%
EBIT Next 5Y23.96%
FCF growth 1Y-24.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.12%
OCF growth 3YN/A
OCF growth 5YN/A